Nickl Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Nickl Therapeutics General Information
Description
Developer of a therapeutics intended for oncology and auto-immune disease. The company develops nk cell and innate lymphoid cell therapies by redirecting the cytotoxic capabilities of nk cells for the precision killing of disease-mediating cells, enabling patients to kill cancer cells and provide improved outcomes.
Contact Information
Corporate Office
- 15 Rue De Huningue
- 68300 Saint-louis
- France
Corporate Office
- 15 Rue De Huningue
- 68300 Saint-louis
- France
Nickl Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 29-Apr-2024 | Completed | Startup |
Nickl Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| General Inception | Venture Capital | Minority |
Nickl Therapeutics FAQs
-
When was Nickl Therapeutics founded?
Nickl Therapeutics was founded in 2023.
-
Where is Nickl Therapeutics headquartered?
Nickl Therapeutics is headquartered in Saint-louis, France.
-
What industry is Nickl Therapeutics in?
Nickl Therapeutics’s primary industry is Other Healthcare Services.
-
Is Nickl Therapeutics a private or public company?
Nickl Therapeutics is a Private company.
-
What is Nickl Therapeutics’s current revenue?
The current revenue for Nickl Therapeutics is .
-
Who are Nickl Therapeutics’s investors?
General Inception has invested in Nickl Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
